Lumenis Revenue and Competitors
Estimated Revenue & Valuation
- Lumenis's estimated annual revenue is currently $446.5M per year.
- Lumenis's estimated revenue per employee is $251,000
Employee Data
- Lumenis has 1779 Employees.
- Lumenis grew their employee count by -3% last year.
Lumenis's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Personal Assistant To VP | Reveal Email/Phone |
3 | VP, HR | Reveal Email/Phone |
4 | VP Sales, US Vision | Reveal Email/Phone |
5 | VP Finance and Operations - Americas | Reveal Email/Phone |
6 | VP Operations | Reveal Email/Phone |
7 | VP Aesthetics, North America | Reveal Email/Phone |
8 | Controller | Reveal Email/Phone |
9 | Head Sales and Education Vision DACH | Reveal Email/Phone |
10 | Controller | Reveal Email/Phone |
Lumenis Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $117.5M | 468 | 5% | N/A | N/A |
#2 | $300M | 823 | 2% | $24.5M | N/A |
#3 | $93.4M | 372 | 6% | N/A | N/A |
#4 | $222M | 1109 | 52% | $90.5M | N/A |
#5 | $84.2M | 289 | 19% | N/A | N/A |
What Is Lumenis?
Energy to Healthcare\r\n\r\nLumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). \r\n\r\nFor nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods in each and every one of the verticals we operate in. \r\n\r\nOur drive for innovation stems from an uncompromising commitment to improving the health and well-being of our patients; addressing new and growing needs of aging populations; and in offering medical professionals cutting-edge solutions that fit seamlessly into the health-economics environment of the 21st century.\r\n\r\nA Leader with Great Assets in Attractive Growing Markets\r\n\r\nInnovative technology: Over 270 registered patents and more than 100 FDA clearances.\r\nGlobal reach: Active installed base of more than 80,000 systems and presence in over 100 countries.\r\n\r\nStrong brand: The Lumenis name and brand are associated with high quality among consumers.\r\n\r\nPartnership with key opinion leaders (KOL’s): Strong KOL support and commitment to research and development.
keywords:N/AN/A
Total Funding
1779
Number of Employees
$446.5M
Revenue (est)
-3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Lumenis News
Photomedex, Lumenis, Ellex, Biolase, Boston Scientific, Quantel, Topcon, Sciton, Alma Lasers, Photomedex. This comprehensive Medical Laser Devices Market...
Cynosure, Lumenis, Alma Lasers, Abbott Laboratories, Boston Scientific, IPG Photonics, Spectranetics, Biolitec AG, Fotona d.o.o., BISON MEDICAL.
Aerolase Corp., Lumenis Ltd., El. En SpA, Cynosure Cutera Alma Lasers, Sciton Sharplight Technologies Ltd., Solta Medical and Syneron...
LOS ANGELES, Aug. 17, 2021 /PRNewswire/ -- Lumenis, Ltd., the world's largest energy-based medical device company for aesthetic, surgical, and ophthalmic applications is proud to announce the launch of SmoothGlo, a novel, nonsurgical approach to addressing the three most visible signs of aging ...
YOKNE'AM ILLIT, Israel, April 29, 2021 /PRNewswire/ -- Lumenis Ltd., the world's largest energy-based medical device company for ophthalmic, aesthetic and surgical applications and the inventor of intense pulsed light (IPL) technology, today announced that the FDA has granted De Novo authoriza ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $364.4M | 1795 | 31% | N/A |
#2 | $603.1M | 1917 | 10% | $578.7M |
#3 | $417.2M | 2055 | 6% | N/A |
#4 | $736.2M | 2340 | 8% | $14M |
#5 | $687.9M | 2358 | 6% | $53M |